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Abstract
Adjuvant radiation therapy (ART) is recommended without consideration of radical prostatectomy Gleason score (RP GS) for cases
with adverse features. We compared the outcomes of pathologically localized high-grade (GS 8–10) prostate cancer (PC) with those
of pT3 GS 7 PC.
A total of 1585 men who underwent RP between 1995 and 2015 comprised the cohort, which was divided into group 1 (RP GS 7
(3+4) and pT3; n=760), group 2 (RP GS 7(4+3) and pT3; n=565), and group 3 (RP GS 8–10 and pT2; n=260). Biochemical
recurrence (BCR), all-cause mortality (ACM), and PC-specific mortality (PCSM) risk were compared among groups using Cox
regression and competing risk analysis.
At a median follow-up of 58 months (interquartile range: 37–85), 721 men experienced BCR and 84 died (22 due to PC). BCR-free
survival rates were lower in group 3 than in group 1 (P< .001); nevertheless, no difference was observed between groups 2 and 3
(P= .638). Furthermore, no difference in ACM was noted among groups. PCSM rates were higher in group 3 than in groups 1 and 2
(P= .001 andP= .005, respectively). This association persisted inmultivariatemodels after adjustment for clinicopathological variables.
Patients with RP GS 8–10 and pT2 PC had higher BCR and PCSM rates than those with RP GS 7 and pT3 PC. Localized high-
grade PC should be considered in decision-making for ART.
Abbreviations: ACM = all-cause mortality, ADT = androgen-deprivation therapy, ART = adjuvant radiation therapy, BCR =
biochemical recurrence, BCRFS = biochemical recurrence-free survival, CRPC = castration-resistant prostate cancer, EPE =
extraprostatic extension, GS =Gleason score, LNI = lymph node invasion, PC = prostate cancer, PCSM = prostate cancer-specific
mortality, PSA = prostate-specific antigen, PSM = positive surgical margin, RP = radical prostatectomy, SVI = seminal vesicle
invasion.
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1. Introduction
The prostate cancer (PC) grading system had undergone 2 major
updates since its introduction in 1974 by Gleason and
Mellinger,[1] with the current application of Gleason score
(GS) differing from that of the original system. Despite revisions,
biopsy GS 8–10 remains to be considered to denote high risk and
is one of the most important prognostic indicators in the
evaluation and treatment of men with PC.[2]
Clinical staging of PC involves the assessment of disease extent
using pretreatment variables and includes digital rectal examina-
tion, measurement of prostate-specific antigen (PSA) level, biopsy
GS, and radiologic imaging. Pathological staging of PC after
radical prostatectomy (RP) is determined by histologic identifi-
cation of tumor extent in the prostate, seminal vesicles, and pelvic
lymph nodes, if lymphadenectomy is performed. Pathological
staging more accurately estimates disease burden and is more
useful than clinical staging in predicting outcomes.[3] GS, surgical
margin status, T stage (extraprostatic extension [EPE], seminal
vesicle invasion [SVI]), and pelvic lymph node invasion (LNI) are
the most important pathological criteria used in predicting
prognosis after RP.[3–7] Both biochemical recurrence-free survival
(BCRFS) and PC-specific mortality (PCSM) are associated with
these pathological features of the disease.[8] As expected,
pathologically localized disease (pT2) shows significantly better
outcomes than locally advanced disease (pT3).[9]
The current guidelines recommend adjuvant androgen-depri-
vation therapy (ADT) for patients with LNI and adjuvant
radiation therapy (ART) for patients with other adverse
pathological features (positive surgical margin [PSM], EPE, or
SVI) or detectable PSA after RP without consideration of RP
GS.[10–12] Whether adjuvant therapy is necessary when RP GS is
high (8–10) remains controversial.[13–15] Several studies analyzed
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predictors of biochemical recurrence (BCR) after adjuvant
therapy to identify patients whomight benefit from radiotherapy;
nonetheless, the predictive impact of high RP GS was not
consistent.
In the event of discord between RPGS and pathological T stage
as regards risk classification, the oncological outcomes and
application of ART are questionable. We hypothesized that the
survival outcomes of men with localized (pT2) high-grade PC
might be worse than or similar to those of men with RP GS 7 and
locally advanced (pT3) PC. The present study aimed to evaluate
whether oncological and survival outcomes of men with RP GS
8–10 and pT2would be different from those of menwith RPGS 7
and pT3.
2. Patients and methods
This retrospective study received approval from the institutional
review board (IRB) of Yonsei University Severance Hospital (IRB
number:4–2018–0206) for the collectionofdata onall patientswho
underwent RP for PC at our institution between 1995 and 2015.
A total of 1585 men with RP GS 7 and pT3 or RP GS 8–10 and
pT2 were identified. Patients who received neoadjuvant therapy,
had metastatic disease at initial diagnosis or LNI during RP, and
had incomplete clinicopathological or follow-up data were
excluded. Considering that GS 7(3+4) and GS 7(4+3) show
different prognosis,[16] the cohort was divided into the following
3 groups according to RP GS and pT stage: group 1, which
comprised 760 men with RP GS 7(3+4) and pT3; group 2, which
consisted of 565 men with RP GS 7(4+3) and pT3; and group 3,
which comprised 260 men with RP GS 8–10 and pT2.
Pathological stages were assigned in accordance with the
American Joint Committee on Cancer staging system.[4]
Pathological analysis of RP specimens was performed by an
experienced uropathologist at our institute.[17] Briefly, the entire
surface of the resected prostate specimens was coated with India
ink, fixed in neutral buffered formalin, and embedded in paraffin
blocks. Whole-mount step sections were transversely cut at
regular intervals from the apex of the prostate to the tips of the
seminal vesicles. Each section was examined for SVI, EPE, and
PSM.
Postoperative PSA follow-up was undertaken at 3-month
intervals for the first 2 years and at 6-month intervals for the
subsequent 3 years; annual PSA follow-up was recommended
thereafter. Adjuvant or salvage radiotherapy was administered at
the discretion of the surgeon.
BCR was defined as detectable PSA after RP, 2 consecutive
increases of≥0.2ng/ml in PSA level with undetectable PSA after RP,
or any secondary treatment after surgery.[18,19] BCRFS was defined
as the time fromRP to theoccurrenceofBCR.Dataonmortality and
cause of death were collected from medical records in the Cancer
Registry Center database at our institution. PCSM was defined as
death due to PC or death attributable to castration-resistant PC
(CRPC) in patients. CRPC was defined as biochemical, radiologic,
or clinical progression in a low-testosterone environment.[20]
Baseline characteristics and pathological outcomes were
compared using Chi-Squared test for categorical data and
Kruskal–Wallis test for continuous data. BCRFS and all-cause
mortality (ACM) were estimated using the Kaplan–Meier
method, and log-rank test was used to compare these estimates
among groups. Multivariate Cox regression analyses were
performed to identify predictive factors for BCR and ACM.
PCSM was calculated and compared among groups using a
competing risk model. A cumulative incidence function was
generated for each group. Multivariate competing risk regression
analysis of PCSMwas performed with death from other causes as
the competing event.[21] The level of significance was set at 0.05 in
all analyses. All statistical analyses were performed using R
version 3.5.1 (R Foundation for Statistical Computing, Vienna,
Austria; http://www.r-project.org) and its cmprsk and rms
packages.
3. Results
Baseline characteristics of patients are summarized in Table 1.
Significant differences in age, PSA level, year of surgery, and PSM





Group 2† Group 3‡
No. patients 760 565 260
Age, years (median [IQR]) 66 (61–70) 67 (62–71) 67 (61–72)
PSA, ng/ml (median [IQR]) 8.65 (5.83–13.48) 10.65 (6.75–18.31) 10.65 (6.54–19.03)
Year of surgery (median [IQR]) 2011 (2009–2013) 2010 (2008–2012) 2012 (2009–2014)
Surgical method
Open 153 (20.1) 135 (23.9) 55 (21.2)
Robotic 594 (78.2) 421 (74.5) 202 (77.7)
Laparoscopic 13 (1.7) 9 (1.6) 3 (1.2)
PSM 454 (59.7) 365 (64.6) 93 (35.8)
EPE 687 (90.4) 451 (79.8) –
SVI 73 (9.6) 114 (20.2) –
Follow-up, months, (median [IQR]) 58 (36–82) 61 (39–90) 48.5 (35–79)
BCR 269 (35.4) 309 (54.7) 143 (55.0)
PCSM 5 (0.7) 7 (1.2) 10 (3.8)
ACM 32 (4.2) 35 (6.2) 17 (6.5)
∗
Radical prostatectomy Gleason score 7(3+4) and pathological T3.
† Radical prostatectomy Gleason score 7(4+3) and pathological T3.
‡ Radical prostatectomy Gleason score 8 and pathological T2.
Data are expressed as N (%) unless otherwise specified.
ACM = all-cause mortality, BCR = biochemical recurrence, EPE = extraprostatic extension, IQR = interquartile range, PCSM = prostate cancer-specific mortality, PSA = prostate-specific antigen, PSM =
positive surgical margin, SVI = seminal vesicle invasion.
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higher preoperative PSA level than group 1. Group 3 showed
lower PSM rate than the other groups. There is no difference in
proportion of surgical methods among the 3 groups (groups 1
and 2: P= .259, groups 1 and 3: P= .784, groups 2 and 3:
P= .590, overall: P= .536).
Of 1585 men, 721 experienced BCR and 84 died (22 due to
PC) at a median follow-up of 58 months (interquartile range: 37–
85). The 10-year BCRFS rates were 50.9%, 33.2%, and 28.6% in
groups 1, 2, and 3, respectively. BCRFS was worse in group 3
than in the other groups (group 1: P< .001, group 2: P= .638,
overall: P< .001; Fig. 1). No significant difference in ACM was
noted among groups (Fig. 2). The 15-year ACM rates were
27.2%, 25.6%, and 50.8% in groups 1, 2, and 3, respectively.
PC-specific survival rates were significantly lower in group 3 than
in groups 1 and 2 (P= .001, P= .005, respectively; Fig. 3).
Specifically, the 15-year PCSM rates were 2.1%, 8.9%, and
42.6% in groups 1, 2, and 3, respectively.
In multivariate models, BCR was higher in group 2 (adjusted
hazard ratio [AHR], 1.625; 95% confidence interval [CI]: 1.305–
2.022; P< .001) and group 3 (AHR, 1.928; 95% CI: 1.387–
2.679; P< .001) than in group 1 (Table 2). Nevertheless, our
group classification was not associated with ACM (Table 3).
PCSM was higher in group 2 (AHR, 1.187; 95% CI: 0.336–
3.850; P= .770) and group 3 (AHR, 5.306; 95% CI: 1.517–
18.560; P= .009) than in group 1 (Table 4).
4. Discussion
Pathological features including RP GS, surgical margin status,
EPE, SVI, and LNI status are the strongest prognostic factors for
predicting postoperative outcomes. Approximately 30% of
patients treated with RP exhibit PSM, EPE, and SVI.[22] Post-
RP recurrence rates in patients with these pathological findings
may be greater than 60% at 5 years.[23] Therefore, most current
guidelines recommend that ART should be offered to patients
with adverse features (PSM, EPE, SVI, or detectable PSA), as ART
has been shown to reduce BCR, local recurrence, and clinical
progression. However, these guidelines do not take RP GS into
account in the decision-making for patient selection for
ART.[10,12]
ADT is recommendedwhen PSA is persistently detected despite
ART.[10] Although ADT is initially effective in hindering tumor
growth, the disease may progress to an androgen-independent
state. This state, which is also known as CRPC, is generally
characterized by poor prognosis and an average survival ranging
from 10 to 20 months.[24] Thus, identifying patients who may
benefit from ART is crucial.
Several clinicians differ in their opinions and practice with
respect to the adoption of ART, notwithstanding the guide-
lines.[25] This variability results from the concern about
functional complications (e.g., incontinence, sexual dysfunction),
as well as its oncological benefit that may not be clinically
significant, even uncertain.[26,27] Swanson et al concluded that the
risk of BCR in men with locally advanced disease varies widely
depending on the preoperative PSA level (<10 vs ≥10ng/ml) and
Figure 1. Kaplan–Meier plots of biochemical recurrence-free survival.
Figure 2. Kaplan–Meier plots of all-cause mortality.
Figure 3. Cumulative incidence functions of prostate cancer-specificmortality.
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RP GS (<7 vs ≥7).[22] In addition, Kang et al evaluated patients
with adverse features who qualified for ART based on the current
American Urological Association and American Society for
Radiation Oncology guidelines. They reported that only 16.6%
of these patients who had adverse features developed BCR and
that BCR occurred in only 3 out of 87 patients with preoperative
PSA level<6.35ng/ml and GS<8. Thus, they recommended that
patient selection for ART should be more customized to avoid
significant overtreatment.[28]
Previous studies have indicated the association between RP GS
and BCR after RP. Menon et al analyzed the oncological
outcomes of patients undergoing robot-assisted RP and reported
Table 2
Cox regression analysis of predictors of biochemical recurrence.
Univariable model Multivariable model
HR (95% CI) P value AHR (95% CI) P value
Age 1.009 (0.998–1.020) .102 1.014 (0.999–1.029) .076
PSA 1.007 (1.006–1.009) <.001 1.005 (1.002–1.007) <.001
Year of surgery 1.021 (0.995–1.047) .113 1.025 (0.990–1.060) .164
Surgical margin
Negative 1 (reference) 1 (reference)
Positive 2.193 (1.868–2.576) <.001 2.098 (1.614–2.727) <.001
Group
∗
1 1 (reference) 1 (reference)
2 1.833 (1.556–2.159) <.001 1.625 (1.305–2.022) <.001
3 1.945 (1.587–2.384) <.001 1.928 (1.387–2.679) <.001
∗
Group 1—radical prostatectomy Gleason score 7(3+4) and pathological T3, group 2—radical prostatectomy Gleason score 7(4+3) and pathological T3, group 3—radical prostatectomy Gleason score 8 and
pathological T2.
AHR= adjusted hazard ratio, CI= confidence interval, PSA=prostate-specific antigen.
Table 3
Cox regression analysis of predictors of all-cause mortality.
Univariable model Multivariable model
HR (95% CI) P value AHR (95% CI) P value
Age 1.108 (1.068–1.150) <.001 1.114 (1.071–1.158) <.001
PSA 1.002 (0.998–1.006) .357 1.001 (0.996–1.006) .679
Year of surgery 0.925 (0.862–0.992) .029 0.926 (0.862–0.996) .038
Surgical margin
Negative 1 (reference) 1 (reference)
Positive 1.398 (0.884–2.221) .152 1.177 (0.720–1.923) .516
Group
∗
1 1 (reference) 1 (reference)
2 1.258 (0.777–2.037) .350 1.042 (0.640–1.697) .868
3 1.576 (0.871–2.852) .133 1.346 (0.720–2.517) .351
∗
Group 1—radical prostatectomy Gleason score 7(3+4) and pathological T3, group 2—radical prostatectomy Gleason score 7(4+3) and pathological T3, group 3—radical prostatectomy Gleason score 8 and
pathological T2.
AHR= adjusted hazard ratio, CI= confidence interval, PSA=prostate-specific antigen.
Table 4
Competing risks analysis of predictors of prostate cancer-specific mortality.
Univariable model Multivariable model
HR (95% CI) P value AHR (95% CI) P value
Age 1.070 (0.996–1.140) .067 1.054 (0.978–1.140) .170
PSA 1.000 (0.997–1.010) .430 0.996 (0.989–1.000) .280
Year of surgery 0.895 (0.791–1.010) .077 0.923 (0.811–1.050) .230
Surgical margin
Negative 1 (reference) 1 (reference)
Positive 3.030 (1.040–8.860) .043 2.065 (0.669–6.370) .210
Group
∗
1 1 (reference) 1 (reference)
2 1.500 (0.486–4.620) .480 1.187 (0.336–3.850) .770
3 5.460 (1.888–15.79) .002 5.306 (1.517–18.560) .009
∗
Group 1—radical prostatectomy Gleason score 7(3+4) and pathological T3, group 2—radical prostatectomy Gleason score 7(4+3) and pathological T3, group 3—radical prostatectomy Gleason score 8 and
pathological T2.
AHR= adjusted hazard ratio, CI= confidence interval, PSA=prostate-specific antigen.
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that one of the strongest predictors of BCRwas RPGS 8–10 (HR,
5.37; 95% CI: 2.99–9.65; P< .0001).[5] Similarly, Eisenberg et al
evaluated the outcomes of patients with pT3aN0 PC and
observed that RP GS was significantly associated with BCR (HR,
1.84; 95% CI: 1.6–2.1; P< .0001).[6] Furthermore, Suardi et al
investigated BCRFS in patients treated with robot-assisted RP;
they reported that the 3-, 5-, and 7-year BCRFS rates for RP GS
8–10 were lower than those for RP GS  7 and that RP GS 8–10
was an independent predictor of BCR (HR, 5.14; P= .004).[29]
Comparable to the relationship between BCR and RP GS,
PCSMwas higher in patients with RP GS 8–10 than in those with
RP GS  7, with high RP GS being a significant risk factor for
PCSM. Freedland et al analyzed PCSM in men who exhibited
BCR after RP and reported that RP GS was one of the
independent predictors of time to PCSM following BCR (HR,
2.26; 95% CI: 1.35–3.77; P= .002).[7] Abdollah et al reported
that RPGS≥8was an independent predictor of PCSM (HR, 5.62;
95% CI: 3.08–10.23; P< .001).[30] Collectively, these findings
indicated that RP GS was strongly associated with prognosis.
Nonetheless, there has been controversy as to whether
adjuvant therapy is necessary when RP GS is ≥8. Van der
Kwast et al analyzed pathological data on specimens from
participants in the randomized controlled European Organisa-
tion for Research and Treatment of Cancer trial 22,911 and
identified no statistically significant predictive impact of RP GS
(P> .1).[13] Kamat et al investigated BCRFS in patients who
received ART for PSM and reported that GS ≥ 7(4+3) was
predictive of BCR in univariate analysis, but not in multivariate
analysis.[14] Conversely, Taille et al evaluated ART failure in
patients with BCR after RP and showed that GS (P= .0395) was
an independent predictive factor.[31]
In the present study, we evaluated whether survival outcomes
(BCRFS, ACM, and PCSM) of men with RP GS 8–10 and pT2
would be different from those of men with RP GS 7 and pT3. In
addition, we aimed to identify whether patients with high RP GS
could be considered for ART, despite having localized PC. We
observed decreasing trends for both BCRFS and cancer-specific
survival with increasing RPGS, irrespective of pathological stage.
Specifically, group 1 showed significantly higher BCRFS than the
other groups; however, no significant difference in BCRFS rates
was noted between groups 2 and 3. PCSM rates were not
significantly different between groups 1 and 2, with PCSM being
higher in group 3 than in the other groups. Moreover, PSA, PSM,
and our group classification were predictors of BCR in
multivariate Cox regression analysis. Preoperative PSA level
was used for risk classification, and PSM was one of the adverse
features to consider ART.[10] In our group classification, groups 2
and 3 showed higher BCR than group 1, with the AHR for group
3 being higher than that for group 2. Additionally, group 3 was
the only predictor of PCSM in multivariate competing risk
analysis. Overall, high RP GS was associated with aggressive
tumor behavior, which increased BCR and PCSM. These findings
implied that RP GS might have more impact on survival
outcomes than pathological T stage; hence, high RP GS should be
included as one of the criteria for selecting patients who might
benefit from ART. Moreover, ART can be used less aggressively
for low or intermediate RP GS disease, even though the disease is
not localized.
This study has several limitations. First, all data from a single
institution were retrospectively reviewed; therefore, our results
may not be generalizable. Second, data on adjuvant or salvage
therapy were not presented because only a fewmen received ART
and salvage therapy could act as a surrogate marker of
BCR.[32,33] Further studies evaluating oncological outcomes
after ART in a large number of patients with localized high-
grade PC and locally advanced low-grade PC are required to
confirm our results. Third, the present study cohort was not
reclassified in accordance with the updated Gleason grading
system because our institution adopted the system in 2016. A
major change in the 2014 update by the International Society of
Urological Pathology was a restrictive definition of grade
pattern 3. As some cases of RP GS 7might have shifted up to RP
GS 8, updated RPGS 8 disease may have a better prognosis than
what our study results implied. However, Gleason pattern 5 has
remained unchanged in the updated Gleason grading sys-
tem.[16] Therefore, the current results should be reassessed in
accordance with the updated Gleason grading system. Finally,
comorbidity variables and a tertiary Gleason pattern in RP GS
were not included in the model.
5. Conclusion
Patients with RP GS 8–10 and pT2 PC had higher BCR and
PCSM rates than those with RP GS 7 and pT3 PC. These findings
suggest that worse oncological outcomes despite localized disease
could be attributed to high RP GS. Thus, high RP GS should be
considered in decision-making for adjuvant treatment. ART can
be more aggressive for localized high-grade PC but less aggressive
for locally advanced low-grade PC.
Author contributions
Conceptualization: Ji Eun Heo, Jee Soo Park, Won Sik Ham.
Data curation: Ji Eun Heo, Jongchan Kim.
Formal analysis: Ji Eun Heo, Jong Soo Lee.
Investigation: Jongchan Kim, Won Sik Jang, Koon Ho Rha.
Methodology: Jee Soo Park, Jongchan Kim.
Project administration: Young Deuk Choi, Sung Joon Hong.
Resources: Won Sik Jang, Koon Ho Rha, Young Deuk Choi,
Sung Joon Hong.
Supervision: Won Sik Ham.
Validation: Jong Soo Lee, Won Sik Jang.
Visualization: Jee Soo Park, Jong Soo Lee.
Writing – original draft: Ji Eun Heo.
Writing – review & editing: Won Sik Ham.
ORCiD: https://orcid.org/0000-0003-2246-8838
References
[1] Gleason DF, Mellinger GT. Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging.
J Urol 1974;111:58–64.
[2] D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome
after radical prostatectomy, external beam radiation therapy, or
interstitial radiation therapy for clinically localized prostate cancer.
JAMA 1998;280:969–74.
[3] Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after
anatomic radical retropubic prostatectomy. Patterns of recurrence and
cancer control. Urol Clin North Am 1997;24:395–406.
[4] Amin MB. American Joint Committee on CAJCC Cancer Staging
Manual. New York: Springer; 2017.
[5] Menon M, Bhandari M, Gupta N, et al. Biochemical recurrence
following robot-assisted radical prostatectomy: analysis of 1384 patients
with a median 5-year follow-up. Eur Urol 2010;58:838–46.
[6] EisenbergMS, Karnes RJ, Kaushik D, et al. Risk stratification of patients
with extraprostatic extension and negative lymph nodes at radical
prostatectomy: identifying optimal candidates for adjuvant therapy. J
Urol 2013;190:1735–41.
Heo et al. Medicine (2019) 98:42 www.md-journal.com
5
[7] Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate
cancer-specific mortality following biochemical recurrence after radical
prostatectomy. JAMA 2005;294:433–9.
[8] Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival
rates following anatomical radical retropubic prostatectomy in 3,478
consecutive patients: long-term results. J Urol 2004;172:910–4.
[9] Van Poppel H, Goethuys H, Callewaert P, et al. Radical prostatectomy
can provide a cure for well-selected clinical stage T3 prostate cancer. Eur
Urol 2000;38:372–9.
[10] Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version
1.2016. J Natl Compr Canc Netw 2016;14:19–30.
[11] Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate
cancer. part 1: screening, diagnosis, and local treatment with curative
intent-update 2013. Eur Urol 2014;65:124–37.
[12] Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage
radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 2013;
190:441–9.
[13] Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of
patients with prostate cancer who benefit from immediate postoperative
radiotherapy: EORTC 22911. J Clin Oncol 2007;25:4178–86.
[14] Kamat AM, Babaian K, Cheung MR, et al. Identification of factors
predicting response to adjuvant radiation therapy in patients with
positive margins after radical prostatectomy. J Urol 2003;170:1860–3.
[15] De la Taille A, Flam T, Thiounn N, et al. Predictive factors of radiation
therapy for patients with prostate specific antigen recurrence after radical
prostatectomy. BJU international 2002;90:887–92.
[16] Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of
Urological Pathology (ISUP) consensus conference on Gleason grading of
prostatic carcinoma: definition of grading patterns and proposal for a
new grading system. Am J Surg Pathol 2016;40:244–52.
[17] Jang WS, Kim LH, Yoon CY, et al. Effect of preoperative risk group
stratification on oncologic outcomes of patients with adverse pathologic
findings at radical prostatectomy. PLoS One 2016;11:e0164497.
[18] Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of
biochemical recurrence in patients treated for localized prostate cancer:
the American Urological Association Prostate Guidelines for Localized
Prostate Cancer Update Panel report and recommendations for a
standard in the reporting of surgical outcomes. J Urol 2007;177:540–5.
[19] Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a
straightforward tool for improved prediction of outcomes after radical
prostatectomy. Cancer 2011;117:5039–46.
[20] Tombal B. Non-metastatic CRPC and asymptomatic metastatic
CRPC: which treatment for which patient? Ann Oncol 2012;23(suppl
10):x251–8.
[21] Fine JP, Gray RJ. A proportional hazards model for the subdistribution
of a competing risk. J Am Stat Assoc 1999;94:496–509.
[22] Swanson GP, Riggs M, Hermans M. Pathologic findings at radical
prostatectomy: risk factors for failure and death. Urol Oncol
2007;25:110–4.
[23] Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after
radical prostatectomy for high-risk prostate cancer: long-term results of a
randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018–27.
[24] Di Zazzo E, Galasso G, Giovannelli P, et al. Estrogens and their receptors
in prostate cancer: therapeutic implications. Front Oncol 2018;8:2.
[25] Kim SP, Tilburt JC, Karnes RJ, et al. Variation in treatment
recommendations of adjuvant radiation therapy for high-risk prostate
cancer by physician specialty. Urology 2013;82:807–12.
[26] Showalter TN, Ohri N, Teti KG, et al. Physician beliefs and practices for
adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat
Oncol Biol Phys 2012;82:e233–8.
[27] Porter CR, Capitanio U, Perrotte P, et al. Adjuvant radiotherapy after
radical prostatectomy shows no ability to improve rates of overall
and cancer-specific survival in a matched case-control study. 2009;
103:597–602.
[28] Kang JH, Ha YS, Kim S, et al. Concern for overtreatment using the AUA/
ASTRO guideline on adjuvant radiotherapy after radical prostatectomy.
BMC Urol 2014;14:30.
[29] Suardi N, Ficarra V, Willemsen P, et al. Long-term biochemical
recurrence rates after robot-assisted radical prostatectomy: analysis of
a single-center series of patients with a minimum follow-up of 5 years.
Urology 2012;79:133–8.
[30] Abdollah F, Suardi N, Cozzarini C, et al. Selecting the optimal candidate
for adjuvant radiotherapy after radical prostatectomy for prostate
cancer: a long-term survival analysis. Eur Urol 2013;63:998–1008.
[31] de la Taille A, Flam TA, Thiounn N, et al. Predictive factors of radiation
therapy for patients with prostate specific antigen recurrence after radical
prostatectomy. BJU Int 2002;90:887–92.
[32] ChalfinHJ, DinizoM, Trock BJ, et al. Impact of surgical margin status on
prostate-cancer-specific mortality. BJU Int 2012;110:1684–9.
[33] Wright JL, Dalkin BL, True LD, et al. Positive surgical margins at radical
prostatectomy predict prostate cancer specific mortality. J Urol 2010;
183:2213–8.
Heo et al. Medicine (2019) 98:42 Medicine
6
